Potent cross-reactive neutralization of SARS coronavirus isolates by human monoclonal antibodies

Zhu, Zhongyu; Chakraborti, Samitabh; He, Yuxian; Roberts, Anjeanette; Tim, Sheahan,; Xiao, Xiaodong; Hensley, Lisa E.; Prabakaran, Ponraj; Rockx, Barry; Sidorov, Igor A.; Corti, Davide; Vogel, Leatrice; Yang, Feng; Kim, Jae-Ouk; Wang, Lin‐Fa; Baric, Ralph S.; Lanzavecchia, Antonio; Curtis, Kristopher M.; Nabel, Gary J.; Subbarao, Kanta; Jiang, Shibo; Dimitrov, Dimiter S.

doi:10.1073/pnas.0701000104

Cited by 298 publications

(340 citation statements)

References 43 publications

Supporting

Mentioning

328

Contrasting

Unclassified

Order By: Relevance

“…have investigated the antiviral activity of a human monoclonal antibody to the S1 protein that blocks receptor association (21), demonstrating the prophylactic effectiveness of this monoclonal antibody in vivo using a mouse model of SARS (9). Recently, several humanized monoclonal antibodies against the S protein have been developed for therapeutic application (22, 23). Many of the neutralizing antibodies against SARS‐CoV recognize a RBD in S1 of the spike protein, but other N‐terminal domains of the S1 and S2 domains also have neutralizing epitopes (8).…”

Section: Discussionmentioning

confidence: 99%

Neutralizing antibody against severe acute respiratory syndrome (SARS)‐coronavirus spike is highly effective for the protection of mice in the murine SARS model

Ishii¹,

Hasegawa²,

Nagata³

et al. 2009

Microbiology and Immunology

View full text Add to dashboard Cite

We evaluated the efficacy of three SARS vaccine candidates in a murine SARS model utilizing lowvirulence Pp and SARS-CoV coinfection. Vaccinated mice were protected from severe respiratory disease in parallel with a low virus titer in the lungs and a high neutralizing antibody titer in the plasma. Importantly, the administration of spike protein-specific neutralizing monoclonal antibody protected mice from the disease, indicating that the neutralization is sufficient for protection. Moreover, a high level of IL-6 and MCP-1 production, but not other 18 cytokines tested, on days 2 and 3 after SARS-CoV infection was closely linked to the virus replication and disease severity, suggesting the importance of these cytokines in the lung pathogenicity of SARS-CoV infection.

show abstract

Section: Discussionmentioning

confidence: 99%

Neutralizing antibody against severe acute respiratory syndrome (SARS)‐coronavirus spike is highly effective for the protection of mice in the murine SARS model

Ishii¹,

Hasegawa²,

Nagata³

et al. 2009

Microbiology and Immunology

View full text Add to dashboard Cite

show abstract

“…The RBD is a major antigenic determinant in the S glycoprotein of the SARS-CoV (Du et al, 2009). Potent human and mouse SARS-CoV neutralizing Ab target the RBD and prevent virus infection by blocking its binding to the ACE2 receptor (He et al, 2005;Zhu et al, 2007). The RBD can elicit broadly neutralizing Ab against diverse isolates, and human monoclonal Ab (mAb) can protect from infection by various zoonotic and human SARS-CoV (He et al, 2006;Zhu et al, 2007).…”

Section: Structural Basis Of Sars Cov Neutralization By Antibodiesmentioning

confidence: 99%

“…Potent human and mouse SARS-CoV neutralizing Ab target the RBD and prevent virus infection by blocking its binding to the ACE2 receptor (He et al, 2005;Zhu et al, 2007). The RBD can elicit broadly neutralizing Ab against diverse isolates, and human monoclonal Ab (mAb) can protect from infection by various zoonotic and human SARS-CoV (He et al, 2006;Zhu et al, 2007). Several conformational epitopes (I-VI) have been defined in the RBD, some of which are conserved in different species (He et al, 2006).…”

Section: Structural Basis Of Sars Cov Neutralization By Antibodiesmentioning

confidence: 99%

A structural view of coronavirus–receptor interactions

et al. 2014

View full text Add to dashboard Cite

In the coronavirus (CoV), the envelope spike (S) glycoprotein is responsible for CoV cell entry and host-to-host transmission. The S is a multifunctional glycoprotein that mediates both attachment of CoV particles to cell surface receptor molecules as well as membrane penetration by fusion. Receptor-binding domains (RBD) have been identified in the S of diverse CoV; they usually contain antigenic determinants targeted by antibodies that neutralize CoV infections. To penetrate host cells, the CoV can use various cell surface molecules, although they preferentially bind to ectoenzymes. Several crystal structures have determined the folding of CoV RBD and the mode by which they recognize cell entry receptors. Here we review the CoV-receptor complex structures reported to date, and highlight the distinct receptor recognition modes, common features, and key determinants of the binding specificity. Structural studies have established the basis for understanding receptor recognition diversity in CoV, its evolution and the adaptation of this virus family to different hosts. CoV responsible for recent outbreaks have extraordinary potential for cross-species transmission; their RBD bear large platforms specialized in recognition of receptors from different species, which facilitates host-to-host circulation and adaptation to man.

show abstract

“…All known bnAbs against HIV-1 are highly divergent from the closest corresponding germline antibodies in contrast to bnAbs against SARS CoV, 77 Nipah and Hendra viruses (henipaviruses), 78 which cause acute infections. Thus, the maturation pathways of HIV-1-specific bnAbs could be much more complex than those of bnAbs against SARS CoV, henipaviruss and likely those for other microbes causing acute infections.…”

Section: Antibodyomesmentioning

confidence: 99%

Therapeutic antibodies, vaccines and antibodyomes

Dimitrov

2010

mAbs

Self Cite

132

129

View full text Add to dashboard Cite

T he potential for antibodies to act as "magic bullets" for treatment of human disease was recognized a century ago, but its full realization has began to occur only during the last decade. A key to their current success is the ability to make libraries of antibodies/B cells, isolate a single species, and engineer it to be safe, efficacious and of high quality. Despite this progress, major challenges to the effective prevention, diagnosis and treatment of a vast majority of diseases remain. Limited success in the development of effective vaccines against diseases such as AIDS and cancer reflects our incomplete understanding of how antibodies are generated and function. Only a miniscule number of antibodies are characterized out of the universe of antibodies generated by the immune system. Knowledge of antibodyomes-the complete sets of antibodies-could help solve these and other challenges.

show abstract

Potent cross-reactive neutralization of SARS coronavirus isolates by human monoclonal antibodies

Abstract: epitope ͉ paratope ͉ vaccine ͉ therapeutic

Cited by 298 publications

References 43 publications

Neutralizing antibody against severe acute respiratory syndrome (SARS)‐coronavirus spike is highly effective for the protection of mice in the murine SARS model

Neutralizing antibody against severe acute respiratory syndrome (SARS)‐coronavirus spike is highly effective for the protection of mice in the murine SARS model

A structural view of coronavirus–receptor interactions

Therapeutic antibodies, vaccines and antibodyomes

Contact Info

Product

Resources

About